1. Home
  2. ELOG vs NEUP Comparison

ELOG vs NEUP Comparison

Compare ELOG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELOG

Eastern International Ltd. Ordinary Shares

N/A

Current Price

$1.08

Market Cap

18.6M

Sector

Industrials

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.07

Market Cap

21.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELOG
NEUP
Founded
2006
1996
Country
China
United States
Employees
N/A
N/A
Industry
Integrated Freight & Logistics
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
18.6M
21.7M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
ELOG
NEUP
Price
$1.08
$4.07
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
121.8K
31.1K
Earning Date
02-27-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
59.27
N/A
EPS
0.16
N/A
Revenue
$45,962,309.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.97
N/A
Revenue Growth
10.64
N/A
52 Week Low
$0.85
$3.65
52 Week High
$3.60
$21.40

Technical Indicators

Market Signals
Indicator
ELOG
NEUP
Relative Strength Index (RSI) 39.24 45.72
Support Level $0.85 $3.94
Resistance Level $1.13 $4.07
Average True Range (ATR) 0.11 0.10
MACD -0.00 0.01
Stochastic Oscillator 43.60 25.49

Price Performance

Historical Comparison
ELOG
NEUP

About ELOG Eastern International Ltd. Ordinary Shares

Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: